Effects of Non-Cytotoxic Concentration of Anticancer Drugs on Doxorubicin Cytotoxicity in Human Breast Cancer Cell Lines

  • Lee, Yoon-Ik (Developmental Therapeutics Program. Michigan Cancer Foundation) ;
  • Lee, Young-Ik (Molecular and Cell Biology Research Division, Korea Research Institute of Bioscience and Biotechnology, KIST)
  • 투고 : 1996.03.04
  • 발행 : 1996.07.31


The effects of non-cytotoxic concentrations of tamoxifen, verapamil, and trifluoperazine on doxorubicin cytotoxicity in five human breast cancer cell lines were studied. A non-cytotoxic concentration of tamoxifen resulted in enhanced doxorubicin cytotoxicity in HTB-123, HTB-26, and MCF-7. In these three cell lines, a combination of tamoxifen with verapamil resulted in even more increased doxorubicin cytotoxicity. Addition of verapamil or trifluoperazine alone did not influence the doxorubicin cytotoxicity significantly. Only in HTB-19 did coincubation with verapamil increase the doxorubicin cytotoxicity. In HTB-123, combination of tamoxifen with trifluoperazine increased the doxorubicin cytotoxicity significantly. In the cell lines where co-incubation with tamoxifen increased doxorubicin sensitivity, high estrogen receptor expression was detected. However, HTB-20, where tamoxifen did not enhance doxorubicin action, was also estrogen receptor positive. None of the cell lines had multidrug resistance related drug efflux and drug retention was not increased by the treatment with tamoxifen and verapamil. Cell cycle traverses were not altered by incubation with tamoxifen, verapamil or combinations thereof. These observatlons suggest mechanism of non-cytotoxic concentrations of tamoxifen and verapamil on doxorubicin cytotoxicity may involve one or more other cellular processes besides those of interference of estrogen binding to its receptor, cell cycle perturbation, or drug efflux blocking.



  1. Cancer Res. v.38 Bachur, N.;Gordon, S.;Gee, M.V.
  2. Cancer Res. v.49 Biswas, R.;Vonderhaar, B.K.
  3. Br. J. Cancer v.71 Callaghan, R.;Higgins, C.F. https://doi.org/10.1038/bjc.1995.59
  4. Cancer Res. v.42 Cozy, E.;Borgana, J.L.;Rochefort, H.
  5. Anthracycline: Current Status and New Developments Crooke, S.T.;Reich, S.D.
  6. Cancer Res. v.43 Ganapathi, R.;Grabowski, D.
  7. In vivo v.6 Kellen, J.A.;Wong, A.C.;Mirakian, A.
  8. J. Cell. Biol. v.66 Krishan, A. https://doi.org/10.1083/jcb.66.1.188
  9. Cancer Res. v.46 Krishan, A.;Sauerteig, A.;Gordon, K.;Swinkin, C.
  10. Cancer Res. v.50 Lerner, L.;Jordan, V.
  11. Cancer Res. v.36 Lippman, M.;Bolan, G.;Huff, K.
  12. Endocrinology v.114 Manni, A.;Wright, C. https://doi.org/10.1210/endo-114-3-836
  13. Cancer Res. v.42 Pearson, O.H.;Manni, A.;Anafah, B.M.
  14. Molecular and Cellular Biology of Mul?tidrug Resistance in Tumor Cells Roninson, I.B.
  15. Cytometry v.9 Ross, D.D.;Ordonez, J.V.;Joneckis, C.C.;Testa, J.R.;Thompson, B.W. https://doi.org/10.1002/cyto.990090413
  16. Cancer Res. v.38 Skovsgaard, T.